CSTONE PHARMA-B(02616): Pujihua (Pulatiene Capsules) has been included in the 2025 National Medical Insurance Catalogue.

CSTONE PHARMA-B (02616) announced that its product PRAHUWA (Pralsetinib capsules, 100 mg) has been included in the latest version of the National Essential Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug List released by the National Medical Security Administration of China. This list will officially take effect on January 1, 2026. PRAHUWA is an orally administered, once-daily targeted therapy drug. The National Medical Products Administration (NMPA) of China has approved PRAHUWA for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients who are RET gene fusion positive and require systemic treatment, advanced or metastatic RET mutated medullary thyroid cancer (MTC) adult and patients aged 12 and above who require systemic treatment, and advanced or metastatic RET fusion-positive thyroid cancer adult and patients aged 12 and above who require systemic treatment and have difficulty with radioactive iodine treatment (if applicable). PRAHUWA has been approved in Hong Kong, China for the treatment of RET gene fusion-positive metastatic NSCLC adult patients, and in Taiwan, China for the treatment of locally advanced or metastatic RET fusion-positive NSCLC, advanced or metastatic RET mutated MTC requiring systemic treatment, and advanced or metastatic RET fusion-positive thyroid cancer adult patients who require systemic treatment and have not responded to radioactive iodine treatment (if applicable). It is marketed in the United States under the brand name GAVRETO by the Food and Drug Administration (FDA) for the treatment of adults with metastatic RET fusion-positive NSCLC confirmed by an FDA-approved test method and adult and pediatric patients aged 12 and above with advanced or metastatic RET fusion-positive thyroid cancer who require systemic treatment and have difficulty with radioactive iodine treatment (if applicable). PRAHUWA was developed by Blueprint Medicines Corporation, a partner of CSTONE PHARMA, which was acquired by Sanofi in July 2025. CSTONE PHARMA has exclusive development and commercialization rights for PRAHUWA in the Greater China region (including Mainland China, Hong Kong, Macau, and Taiwan). In November 2023, CSTONE PHARMA granted the exclusive commercialization rights for PRAHUWA in Mainland China to Shanghai Allist Pharmaceuticals Co., Ltd. Healthcare Technology Corporation.